<NOTICE>
DEPARTMENT OF HEALTH AND HUMAN SERVICES
<SUBAGY>Centers for Medicare & Medicaid Services</SUBAGY>
<DEPDOC>[CMS-4210-N]</DEPDOC>
<SUBJECT>Medicare Program; Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program Draft Guidance; Comment Request</SUBJECT>
<HD SOURCE="HED">AGENCY:</HD>
Centers for Medicare & Medicaid Services, Health and Human Services (HHS).
<HD SOURCE="HED">ACTION:</HD>
Notice.
<SUM>
<HD SOURCE="HED">SUMMARY:</HD>
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' draft guidance for the third cycle of the Medicare Drug Price Negotiation Program, the first cycle of renegotiation, and manufacturer effectuation of the maximum fair price for 2026, 2027, and 2028 for the implementation of the Inflation Reduction Act (IRA).
</SUM>
<DATES>
<HD SOURCE="HED">DATES:</HD>
Comments must be received by Thursday, June 26, 2025.
</DATES>
<HD SOURCE="HED">ADDRESSES:</HD>
Written comments should be sent to
<E T="03">IRARebateandNegotiation@cms.hhs.gov</E>
with the relevant subject line, “Medicare Drug Price Negotiation Program Draft Guidance.” CMS' draft guidance and other Inflation Reduction Act-related guidance can be viewed on the dedicated Inflation Reduction Act section of the CMS website at
<E T="03">https://www.cms.gov/inflation-reduction-act-and-medicare/.</E>
<SUPLINF>
<HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
The Inflation Reduction Act (IRA) (Pub. L. 117-169) was signed into law on August 16, 2022. Sections 11001 and 11002 of the IRA established the Medicare Drug Price Negotiation Program (hereafter the “Negotiation Program”) to negotiate maximum fair prices (MFPs) for certain high expenditure, single source drugs and biological products. The requirements for this program are described in sections 1191 through 1198 of the Social Security Act (the Act) as added by sections 11001 and 11002 of the IRA. The draft guidance describes how CMS intends to implement the Negotiation Program for Initial Price Applicability Year (IPAY) 2028 (January 1, 2028 to December 31, 2028), which includes renegotiation, and specifies the requirements for manufacturer effectuation of the MFPs for 2026, 2027, and 2028.
To obtain copies of the Negotiation Program draft guidance and other IRA-related documents, please access the CMS IRA website by copying and pasting the following web address into your web browser:
<E T="03">https://www.cms.gov/inflation-reduction-act-and-medicare.</E>
If interested in receiving CMS IRA updates by email, individuals may sign up for CMS' IRA email updates at
<E T="03">https://www.cms.gov/About-CMS/Agency-Information/Aboutwebsite/EmailUpdates.</E>
<HD SOURCE="HD1">Signature Authority</HD>
The Administrator of CMS, Dr. Mehmet Oz, having reviewed and approved this document, authorizes Evell J. Barco Holland, who is the Federal Register Liaison, to electronically sign this document for purposes of publication in the
<E T="04">Federal Register</E>
.
<SIG>
<NAME>Evell J. Barco Holland,</NAME>
Federal Register Liaison, Centers for Medicare & Medicaid Services.
</SIG>
</SUPLINF>
<FRDOC>[FR Doc. 2025-08607 Filed 5-12-25; 4:15 pm]</FRDOC>
</NOTICE>
This text is preserved for citation and comparison. View the official version for the authoritative text.